BiotechTube
Solenic Medical

Solenic Medical

San Francisco, United States· Est.
solenic.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $1.2M

Overview

Solenic Medical is developing a novel, non-invasive therapeutic platform targeting biofilm infections on metallic orthopedic implants, a major and costly surgical complication. Its lead investigational device, the SOLA2, has received FDA Investigational Device Exemption (IDE) approval, enabling First-in-Human clinical studies as of August 2024. The company is led by a seasoned executive team with deep experience in medical devices, orthopedics, and technology development, positioning it to address a significant unmet need in the growing joint replacement market.

Infectious DiseaseOrthopedics

Technology Platform

Patented Alternating Magnetic Field (AMF) technology designed to non-invasively generate localized heat on metallic implant surfaces to eradicate bacterial biofilms.

Funding History

1
Total raised:$1.2M
Seed$1.2M

Opportunities

The primary opportunity is addressing the large, costly, and growing unmet need for periprosthetic joint infection treatment, potentially saving billions in healthcare costs and improving patient outcomes.
The platform technology could be expanded beyond knees to other metallic implants (hips, trauma), creating a multi-indication franchise.
A successful non-invasive treatment could command premium pricing and rapid adoption in a market dominated by invasive surgical options.

Risk Factors

Key risks include clinical trial failure to demonstrate safety/efficacy, regulatory hurdles in obtaining PMA approval, and challenges in convincing the medical community to adopt a paradigm-shifting, non-surgical standard of care.
The company is also pre-revenue and dependent on raising capital to fund expensive clinical development.

Competitive Landscape

Direct competition is limited, as no approved non-invasive biofilm eradication devices exist. However, Solenic competes with the entrenched standard of care (revision surgery) and other emerging approaches, including novel antibiotic coatings, local antimicrobial delivery systems, and biofilm-disrupting agents. Established orthopedic giants (e.g., Johnson & Johnson, Stryker, Zimmer Biomet) could develop or acquire competing technologies.

More companies in Small Molecule Drugs →More companies in United States →